Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form FORM 10-Q

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended SeptemberJune 30, 20172023

 

or

 

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to __________

 

Commission file number 000-54123001-38623

 

3PEA INTERNATIONAL,PAYSIGN, INC.

(Exact name of small business issuerregistrant as specified in its charter)

 

Nevada95-4550154
(State or other jurisdiction of incorporation or organization)(IRS Employer Identification No.)

 

1700 W Horizon Ridge2615 St. Rose Parkway Suite 201,,

Henderson, Nevada 8901289052

(Address of principal executive offices) (Zip code)

 

(702)453-2221

(Issuer’sRegistrant’s telephone number, including area code)

_______________________________________________________ 

                           N/A                           

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each ClassTrading SymbolName of each exchange on which registered
Common Stock, $0.001 par value per sharePAYSThe Nasdaq Stock Market LLC

  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yesx Noo

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).xYes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”,filer,” “smaller reporting company”,company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

 

Large accelerated filer oAccelerated filer o
Non-accelerated filerSmaller reporting company
 Non-accelerated filer oSmaller reporting company x
Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.oAct

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yeso ☐ Nox

 

StateIndicate the number of shares outstanding of each of the issuer’s classes of common equity,stock, as of the latest practicable date: 43,660,765 52,753,374 shares as of November 1, 2017.August 4, 2023.

 

   

 

3PEA INTERNATIONAL,PAYSIGN, INC.

 

FORM 10-Q REPORT

INDEX

 

PART I. FINANCIAL INFORMATION3
  
Item 1. Financial Statements3
  
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations1415
  
Item 3. Quantitative and Qualitative Disclosures aboutAbout Market Risk1823
  
Item 4. Controls and Procedures1823
  
PART II. OTHER INFORMATION19
  
Item 1. Legal Proceedings1924
  
Item 1A. Risk Factors1924
  
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds19
Item 3. Defaults upon Senior Securities19
Item 4. Mine Safety Disclosures1924
  
Item 5. Other Information1924
  
Item 6. Exhibits1925
  
SIGNATURES2026

 

 

 

 2 

 

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

3PEA INTERNATIONAL,PAYSIGN, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2017 AND DECEMBER 31, 2016

 

        
 September 30,
2017
(Unaudited)
 December 31,
2016
(Audited)
  

June 30,
2023

(Unaudited)

 

December 31,
2022

(Audited)

 
ASSETS                
        
Current assets                
Cash $1,916,736  $1,631,943  $7,670,677  $9,708,238 
Cash Restricted  12,498,529   10,002,505 
Accounts Receivable  183,521   110,269 
Prepaid Expenses and other assets  521,895   270,634 
Restricted cash  78,365,845   80,189,113 
Accounts receivable, net  7,749,451   4,680,991 
Other receivables  1,238,020   1,439,251 
Prepaid expenses and other current assets  2,290,792   1,699,808 
Total current assets  15,120,681   12,015,531   97,314,785   97,717,401 
                
Fixed assets, net  852,136   300,761   1,124,242   1,255,292 
        
Intangible and other assets        
Deposits  5,551   5,551 
Intangible assets, net  1,524,063   1,550,044   6,998,727   5,656,722 
Operating lease right-of-use asset  3,417,635   3,614,838 
                
Total assets $17,502,431  $13,871,707  $108,855,389  $108,244,253 
                
LIABILITIES AND STOCKHOLDERS' EQUITY                
        
Current liabilities                
Accounts payable and accrued liabilities $806,454  $765,596  $10,484,747  $8,088,660 
Operating lease liability, current portion  372,387   361,408 
Customer card funding  12,498,529   10,002,505   78,365,845   80,189,113 
Legal settlement payable – current portion     254,900 
Notes payable     124,168 
Total current liabilities  13,304,983   11,147,169   89,222,979   88,639,181 
                
Long-term liabilities        
Notes payable     27,892 
Total long-term liabilities     27,892 
Operating lease liability, long term portion  3,122,798   3,311,777 
                
Total liabilities  13,304,983   11,175,061   92,345,777   91,950,958 
                
Commitments and contingencies (Note 8)      
        
Stockholders' equity                
Common stock; $0.001 par value; 150,000,000 shares authorized, 43,660,765 and 43,185,765 issued and outstanding at September 30, 2017 and December 31, 2016, respectively  43,661   43,186 
Preferred stock, $0.001 par value; 25,000,000 shares authorized; none issued and outstanding      
Common stock, $0.001 par value; 150,000,000 shares authorized; 52,842,382 and 52,650,382 issued at June 30, 2023 and December 31, 2022, respectively  52,842   52,650 
Additional paid-in capital  7,085,324   6,797,759   20,595,359   19,137,281 
Treasury stock at cost, 303,450 shares at September 30, 2017 and December 31, 2016  (150,000)  (150,000)
Treasury stock, at cost; 623,008 and 303,450 shares, respectively  (1,127,667)  (150,000)
Accumulated deficit  (2,545,609)  (3,799,613)  (3,010,922)  (2,746,636)
Total 3Pea International, Inc.'s stockholders' equity  4,433,376   2,891,332 
Noncontrolling interest  (235,928)  (194,686)
Total stockholders' equity  4,197,448   2,696,646   16,509,612   16,293,295 
                
Total liabilities and stockholders' equity $17,502,431  $13,871,707  $108,855,389  $108,244,253 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 3 


3PEA INTERNATIONAL,

PAYSIGN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016OPERATIONS

(UNAUDITED)

 

  For the three months ended
September 30,
 
  2017  2016 
Revenues $4,001,991  $2,812,536 
         
Cost of revenues (excluding depreciation and amortization)  2,145,621   1,522,458 
         
Gross profit  1,856,370   1,290,078 
         
Operating expenses        
Depreciation and amortization  276,533   149,342 
Selling, general and administrative  1,104,280   660,556 
         
Total operating expenses  1,380,813   809,898 
         
Income from operations  475,557   480,180 
         
Other income (expense)        
Other income  14,398   4,986 
Interest expense     (20,483)
Total other income (expense)  14,398   (15,497)
         
Income before provision for income taxes and noncontrolling interest  489,955   464,683 
         
Provision for income taxes  3,000    
         
Net income before noncontrolling interest  486,955   464,683 
         
Net loss attributable to noncontrolling interest  13,213   15,746 
         
Net income attributable to 3Pea International, Inc. $500,168  $480,429 
         
Net income per common share - basic $0.01  $0.01 
Net income per common share - fully diluted $0.01  $0.01 
         
Weighted average common shares outstanding - basic  43,474,895   42,948,265 
Weighted average common shares outstanding - fully diluted  44,544,895   43,138,279 

                 
  Three Months Ended
June 30,
  

Six Months Ended

June 30,

 
  2023  2022  2023  2022 
Revenues                
Plasma industry $10,014,461  $7,806,201  $19,374,528  $15,200,565 
Pharma industry  729,236   773,311   1,318,798   1,579,879 
Other  297,354   19,264   491,015   38,971 
Total revenues  11,041,051   8,598,776   21,184,341   16,819,415 
                 
Cost of revenues  5,425,311   3,900,965   10,520,932   7,123,355 
                 
Gross profit  5,615,740   4,697,811   10,663,409   9,696,060 
                 
Operating expenses                
Selling, general and administrative  5,304,625   4,255,976   10,250,075   8,896,888 
Depreciation and amortization  958,001   713,180   1,803,017   1,392,351 
Total operating expenses  6,262,626   4,969,156   12,053,092   10,289,239 
                 
Loss from operations  (646,886)  (271,345)  (1,389,683)  (593,179)
                 
Other income                
Interest income, net  600,867   70,227   1,185,064   84,563 
                 
Loss before income tax provision  (46,019)  (201,118)  (204,619)  (508,616)
Income tax provision  58,137   26,916   59,667   28,813 
                 
Net loss $(104,156) $(228,034) $(264,286) $(537,429)
                 
Net loss per share                
Basic $(0.00) $(0.00) $(0.01) $(0.01)
Diluted $(0.00) $(0.00) $(0.01) $(0.01)
                 
Weighted average common shares                
Basic  52,259,002   51,993,031   52,330,829   51,906,335 
Diluted  52,259,002   51,993,031   52,330,829   51,906,335 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 4 

 

3PEA INTERNATIONAL,PAYSIGN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016STOCKHOLDERS’ EQUITY

(UNAUDITED)

 

  For the nine months ended
September 30,
 
  2017  2016 
Revenues $10,621,055  $7,369,540 
         
Cost of revenues (excluding depreciation and amortization)  5,834,709   4,062,062 
         
Gross profit  4,786,346   3,307,478 
         
Operating expenses        
Depreciation and amortization  725,401   406,328 
Selling, general and administrative  2,847,955   2,054,351 
         
Total operating expenses  3,573,356   2,460,679 
         
Income from operations  1,212,990   846,799 
         
Other income (expense)        
Other income  40,395   10,900 
Interest expense  (31,623)  (58,748)
Total other income (expense)  8,772   (47,848)
         
Income before provision for income taxes and noncontrolling interest  1,221,762   798,951 
         
Provision for income taxes  9,000    
         
Net income before noncontrolling interest  1,212,762   798,951 
         
Net loss attributable to noncontrolling interest  41,242   99,097 
         
Net income attributable to 3Pea International, Inc. $1,254,004  $898,048 
         
Net income per common share - basic $0.03  $0.02 
Net income per common share - fully diluted $0.03  $0.02 
         
Weighted average common shares outstanding - basic  43,308,750   42,844,570 
Weighted average common shares outstanding - fully diluted  44,378,750   42,991,542 

                             
  Common Stock  Additional
Paid-in
  Treasury Stock  Accumulated  Total Stockholders’ 
  Shares  Amount  Capital  Shares  Amount  Deficit  Equity 
Balance, December 31, 2022  52,650,382  $52,650  $19,137,281   (303,450) $(150,000) $(2,746,636) $16,293,295 
                             
Stock issued upon vesting of restricted stock  118,000   118   (118)            
Stock-based compensation        618,244            618,244 
Repurchase of common stock           (200,000)  (666,018)     (666,018)
Net loss                 (160,130)  (160,130)
                             
Balance, March 31, 2023  52,768,382   52,768   19,755,407   (503,450)  (816,018)  (2,906,766)  16,085,391 
                             
Stock issued upon vesting of restricted stock  70,000   70   (70)            
Exercise of stock options  4,000   4   9,596            9,600 
Stock-based compensation        830,426            830,426 
Repurchase of common stock           (119,558)  (311,649)     (311,649)
Net loss                 (104,156)  (104,156)
                             
Balance, June 30, 2023  52,842,382  $52,842  $20,595,359   (623,008) $(1,127,667) $(3,010,922) $16,509,612 

  Common Stock  Additional
Paid-in
  Treasury Stock  Accumulated  Total Stockholders’ 
  Shares  Amount  Capital  Shares  Amount  Deficit  Equity 
Balance, December 31, 2021  52,095,382  $52,095  $16,860,119   (303,450) $(150,000) $(3,774,411) $12,987,803 
                             
Stock issued upon vesting of restricted stock  123,000   123   (123)            
Stock-based compensation        569,502            569,502 
Net loss                 (309,395)  (309,395)
                             
Balance, March 31, 2022  52,218,382   52,218   17,429,498   (303,450)  (150,000)  (4,083,806)  13,247,910 
                             
Stock issued upon vesting of restricted stock  105,000   105   (105)            
Stock-based compensation        488,287            488,287 
Net loss                 (228,034)  (228,034)
                             
Balance, June 30, 2022  52,323,382  $52,323  $17,917,680   (303,450) $(150,000) $(4,311,840) $13,508,163 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

 5 

 

3PEA INTERNATIONAL,PAYSIGN, INC.

CONDENSED CONSOLIDATED STATEMENTSTATEMENTS OF STOCKHOLDERS' EQUITYCASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017(UNAUDITED)

 

  Stockholders' Equity Attributable to 3Pea International, Inc.       
     Additional  Treasury     Non-  Total 
  Common Stock  Paid-in  Stock  Accumulated  controlling  Stockholders' 
  Shares  Amount  Capital  Amount  Deficit  Interest  Equity 
Balance, December 31, 2016 (Audited)  43,185,765  $43,186  $6,797,759  $(150,000) $(3,799,613) $(194,686) $2,696,646 
                             
Issuance of stock for services (Unaudited)  75,000   75   12,807            12,882 
                             
Stock issued for employee bonus (Unaudited)  200,000   200   84,200            84,400 
                             
Stock Based Compensation (Unaudited)        140,758            140,758 
                             
Exercise of Warrants (Unaudited)  200,000   200   49,800            50,000 
                             
Net income (loss) (Unaudited)              1,254,004   (41,242)  1,212,762 
Balance, September 30, 2017 (Unaudited)  43,660,765  $43,661  $7,085,324  $(150,000) $(2,545,609) $(235,928) $4,197,448 

         
  Six Months Ended
June 30,
 
  2023  2022 
Cash flows from operating activities:        
Net loss $(264,286) $(537,429)
Adjustments to reconcile net loss to net cash provided by operating activities:        
Gain on disposal assets  (4,862)  –  
Stock-based compensation expense  1,448,670   1,057,789 
Depreciation and amortization  1,803,017   1,392,351 
Noncash lease expense  197,203   186,862 
Changes in operating assets and liabilities:        
Accounts receivable  (3,068,460)  (94,819)
Other receivable  201,231   (420,033)
Prepaid expenses and other current assets  (590,984)  (511,173)
Accounts payable and accrued liabilities  2,431,087   (190,359)
Operating lease liability  (178,000)  (167,660)
Customer card funding  (1,823,268)  15,683,936 
Net cash provided by operating activities  151,348   16,399,465 
         
Cash flows from investing activities:        
Purchase of fixed assets  (84,911)  (38,188)
Capitalization of internally developed software  (2,959,199)  (1,537,021)
Net cash used in investing activities  (3,044,110)  (1,575,209)
         
Cash flows from financing activities:        
Proceeds from exercise of options  9,600    
Repurchase of common stock  (977,667)   
Net cash used in financing activities  (968,067)   
         
Net change in cash and restricted cash  (3,860,829)  14,824,256 
Cash and restricted cash, beginning of period  89,897,351   68,671,070 
         
Cash and restricted cash, end of period $86,036,522  $83,495,326 
         
Cash and restricted cash reconciliation:        
Cash $7,670,677  $6,527,476 
Restricted cash  78,365,845   76,967,850 
Total cash and restricted cash $86,036,522  $83,495,326 
         
Supplemental cash flow information:        
Non-cash financing activities        
Cash paid for taxes $159,510  $8,700 
Interest paid $  $821 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 6 

 

3PEA INTERNATIONAL,PAYSIGN, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016

(UNAUDITED)

  For the nine months ended
September 30,
 
  2017  2016 
Cash flows from operating activities:        
Net income $1,254,004  $898,048 
Adjustments to reconcile net income to net cash provided by operating activities:        
Change in noncontrolling interest  (41,242)  (99,097)
Depreciation and amortization  725,401   406,328 
Stock based compensation  238,040   40,091 
Changes in operating assets and liabilities:        
Change in accounts receivable  (73,252)  (93,531)
Change in prepaid expenses  (251,261)  4,028 
Change in other assets     (2,000)
Change in accounts payable and accrued liabilities  40,858   237,511 
Change in customer card funding  2,496,024   1,726,127 
Change in legal settlement payable  (254,900)  (746,954)
Net cash provided by operating activities  4,133,672   2,370,551 
         
Cash flows from investing activities:        
Purchase of fixed assets  (649,260)  (52,111)
Purchase of intangible assets  (601,535)  (551,448)
Net cash used in investing activities  (1,250,795)  (603,559)
         
Cash flows from financing activities:        
Proceeds from borrowing on note payable     29,053 
Proceeds from exercise of warrants  50,000    
Payments on notes payable  (152,060)  (126,308)
Net cash used in financing activities  (102,060)  (97,255)
         
Net change in cash and restricted cash  2,780,817   1,669,737 
Cash and restricted cash, beginning of period  11,634,448   8,453,439 
         
Cash and restricted cash, end of period $14,415,265  $10,123,176 
         
Supplemental cash flow information:        
Non-cash financing activities:        
Transfer of accrued interest from accrued liabilities to notes payable $  $115,227 
         
Interest paid $46,663  $58,748 
Income taxes paid $16,200  $ 

See accompanying notes to consolidated financial statements.

7

3PEA INTERNATIONAL, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1.     BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT POLICIES

 

The foregoing unaudited interim condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted accounting principlesin the United States of America (“GAAP”) for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of AmericaGAAP for complete financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2016.2022. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.

 

The preparation of financial statements in accordance with generally accepted accounting principles in the United States of AmericaGAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumptionassumptions are inherent in the preparation of the Company’s financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions that could have a material effect on the reported amounts of the Company’s financial position and results of operations.

 

Operating results for the three and ninesix months ended SeptemberJune 30, 20172023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.2023.

 

About 3PEA International,Paysign, Inc.

 

3PEA International,Paysign, Inc. (the “Company,” “Paysign,” “we” or “our”) was incorporated on August 24, 1995, and trades under the symbol PAYS on The Nasdaq Stock Market LLC. Paysign is a vertically integrated provider of innovative prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing servicesdesigned for corporate, consumerbusinesses, consumers and government applications. Ourinstitutions. Headquartered in Nevada, the company creates customized, innovative payment solutions are utilized by our customers as a means to increase customer loyalty, reduce administration costsfor clients across all industries, including pharmaceutical, healthcare, hospitality and streamline operations. Public sector organizations can utilize our solutions to disburse public benefits or for internal payments. We market our prepaid debit card solutions under our PaySign® brand. As we are a payment processor and debit card program manager, we derive our revenue from all stages of the debit card lifecycle. We provide a card processing platform consisting of proprietary systems and innovative software applications based on the unique needs of our programs. We have extended our processing business capabilities through our proprietary PaySign platform. We provide a variety of services including transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service.retail.

 

We have developed prepaid card programs for healthcare reimbursement payments, pharmaceutical co-pay assistance, donor compensation and corporate incentive and rewards. We plan to expand our product offering to include payroll cards, general purpose re-loadable cards, travel cards, and expense reimbursement and per diem cards. Our cards are offered to end users through our relationships with bank issuers.

Our proprietary PaySign® platform was built on modern cross-platform architecture and designed to be highly flexible, scalable and customizable. The platform allows 3PEA to significantly expand its operational capabilities by facilitating our entry into new markets within the payments space through its flexibility and ease of customization. The PaySign platform delivers cost benefits and revenue building opportunities to our partners.

We manage all aspects of the debit card lifecycle, from managing the card design and approval processes with partners and associations, to production, packaging, distribution, and personalization. We also oversee inventory and security controls, renewals, lost and stolen card management and replacement. We deploy a fully staffed, in-house customer service department which utilizes bi-lingual customer service agents, Interactive Voice Response, (IVR), SMS alerts and two way SMS messaging. 

Principles of consolidationConsolidation – The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.

 

Use of estimatesEstimates – The preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principlesGAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, and(ii) the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and (iii) the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents – The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows. The Company had no cash equivalents at June 30, 2023 and December 31, 2022.

Restricted Cash – At June 30, 2023 and December 31, 2022, restricted cash consisted of funds held specifically for our card product and pharma programs that are contractually restricted to use. The Company includes changes in restricted cash balances with cash and cash equivalents when reconciling the beginning and ending total amounts in our condensed consolidated statements of cash flows.

 

 87 

 

Restricted cashConcentrations of Credit RiskRestricted cash is a cash account controlled byFinancial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash. The Company maintains its cash and cash equivalents and restricted cash in various bank accounts primarily with one financial institution in the United States which fundsat times, may exceed federally insured limits. If this financial institution were to be placed into receivership, we may be unable to access the cash we have on deposit. If we are received relatedunable to the card programs fromaccess our customers.cash and cash equivalents as needed, our financial position and ability to operate our business could be adversely affected. The Company has recorded a corresponding customer card funding liability. Restricted cash is not availableexperienced, nor does it anticipate, any losses with respect to such accounts. As of June 30, 2023 and December 31, 2022, the company for corporate use.Company had approximately $38,206,698 and $43,516,155 in excess of federally insured bank account limits, respectively.

 

GoodwillAs of June 30, 2023, the Company also has a concentration of accounts receivable risk, as two pharma program customers associated with our pharma patient affordability programs each individually represent 35% and intangible14% of our accounts receivable balance. Two pharma program customers each individually represented 35% and 24% of our accounts receivable balance on December 31, 2022.

Fixed Assets – Fixed assets - Goodwill are stated at cost less accumulated depreciation. Depreciation is principally recorded using the purchase premium after adjusting forstraight-line method over the fair value of net assets acquired. Goodwill is not amortized but is reviewed for potential impairment on an annual basis, or when events or circumstances indicate a potential impairment, at the reporting unit level. A reporting unit, as defined under applicable accounting guidance, is a business segment or one level below a business segment. We may in any given period bypass the qualitative assessment and proceed directly to a two-step method to assess and measure impairmentestimated useful life of the reporting unit’s goodwill. We first assess qualitative factorsasset, which is generally 3 to determine whether it10 years. The cost of repairs and maintenance is more likely-than-not (i.e., a likelihoodcharged to expense as incurred. Leasehold improvements are capitalized and depreciated over the shorter of more than 50 percent) that the fair valueremaining lease term or the estimated useful life of the improvements. Expenditures for property betterments and renewals are capitalized. Upon sale or other disposition of a reporting unitdepreciable asset, cost and accumulated depreciation are removed from the accounts and any gain or loss is less than its carrying value. This step serves as the basis for determiningreflected in other income (expense).

The Company periodically evaluates whether it is necessary to perform the two-step quantitative impairment test. The first step of the quantitative impairment test involves a comparisonevents and circumstances have occurred that may warrant revision of the estimated fair valueuseful life of each reporting unit to its carrying amount, including goodwill. Iffixed assets or whether the estimated fair valueremaining balance of fixed assets should be evaluated for possible impairment. The Company uses an estimate of the reporting unit exceeds its carrying amount, goodwillrelated undiscounted cash flows over the remaining life of the reporting unit is not impaired; however, if the carrying amount of the reporting unit exceeds its estimated fair value, then the second step of the quantitative impairment test must be performed. The second step compares the implied fair value of the reporting unit’s goodwill with its carrying amount to measure the amount of impairment loss, if any. The implied fair value of goodwill is determinedfixed assets in the same manner as the amount of goodwill recognized in a business combination. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess.measuring their recoverability.

 

Intangible AssetsFor intangible assets, we recognizethe Company recognizes an impairment loss if the carrying amount of the intangible asset is not recoverable and exceeds its fair value. The carrying amount of the intangible asset is considered not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use of the asset. No impairment was deemed necessary in the three and nine month period ended September 30,2017.

 

Intangible assets with a finite liveslife are amortized on a straight-line basis over theirits estimated useful lives.life, which is generally 3 to 15 years.

Internally Developed Software Costs - Computer software development costs are expensed as incurred, except for internal use software or website development costs that qualify for capitalization as described below, and include compensation and related expenses, costs of hardware and software, and costs incurred in developing features and functionality.

 

PlatformFor computer software developed or obtained for internal use, costs that are incurred in the preliminary project and Licensespost implementation stages of software development are comprised ofexpensed as incurred. Costs incurred during the application and development stage are capitalized. Capitalized costs associated with our development and continual development of our platformare amortized using the straight-line method over a three year estimated useful life, beginning in the period in which includes direct development costs,the software and licenses.is available for use.

 

RevenueContract Assets- Incremental costs to obtain or fulfill a contract with a customer are capitalized. The Company determines the costs that are incremental by confirming the costs (i) are directly related to a customer’s contract, (ii) generate or enhance resources to fulfill contract performance obligations in the future, and expense recognition – We recognize revenue(iii) are recoverable. Amortization is on a straight-line basis generally over three to five years, beginning when (1) there is persuasive evidence of an arrangement existing, (2) delivery has occurred, (3) our pricegoods and services are transferred to the buyer is fixedcustomer or determinable and (4) collectabilitygroup of the receivables is reasonably assured. We recognize the costs of these revenues at the time revenue is recognized. Any fees paid up front are deferred until such time such services have been considered rendered.customers.

Customer Card Funding As of SeptemberJune 30, 20172023 and December 31, 2016, there were no deferred revenues recorded.2022, customer card funding represents funds loaded or available to be loaded on cards for the Company’s card product programs.

 

We generate the following types of revenues:

 

 ·8Administration and usage fees, charged to our prepaid card clients when our programs are created, distributed or reloaded. Such revenues are recognized when such services are performed.

 

·Transaction fees, paid by the applicable networks and passed through by our card issuing banks when our SVCs (Stored Value Cards) are used in a purchase or ATM transaction. Such revenues are recognized when such services are performed.

·Maintenance, administration, transaction fees, charged to an SVC and not under any multiple element arrangements. Such revenues are recognized when such services are performed.

·Program maintenance management fees charged to our clients. Such revenues are not under any multiple element arrangements and are recognized when such services are performed.

·Software development and consulting services to our clients. Such revenues are recognized in accordance with ASC 985-605.

 

The Company records all revenues on gross basis in accordance with ASC 605-45 since it is the primary obligor and establishes the price in the revenue arrangement. The Company is currently under no obligation for refunding any fees or has any obligations for disputed claim settlements.

Earnings (loss) per share-Per Share Basic earnings (loss) per share exclude any dilutive effects of options, warrants and convertible securities. Basic earnings (loss) per share is computed using the weighted-average number of outstanding common stocksshares outstanding during the applicable period. Diluted earnings per share is computed using the weighted-average number of common and common stock equivalent shares outstanding during the period.period using the treasury stock method. Common stock equivalent shares are excluded from the computation if their effect on the diluted earnings per share calculation is antidilutive.anti-dilutive.

 

Revenue and Expense Recognition – In determining when and how revenue is recognized from contracts with customers, the Company performs the following five-step analysis: (i) identification of contracts with customers, (ii) determination of performance obligations, (iii) measurement of the transaction price, (iv) allocation of the transaction price to the performance obligations, and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

 

The Company generates revenues from plasma card programs through fees generated from cardholder fees and interchange fees. Revenues from pharma card programs are generated through card program management fees, transaction claims processing fees, interchange fees, and settlement income.

Plasma and pharma card program revenues include both fixed and variable components. Cardholder fees represent an obligation to the cardholder based on a per transaction basis and are recognized at a point in time when the performance obligation is fulfilled. Card program management fees and transaction claims processing fees include an obligation to our card program sponsors and are generally recognized when earned on a monthly basis and are typically due within 30 days pursuant to the contract terms which are generally multi-year contracts. The Company uses the output method to recognize card program management fee revenue at the amount of consideration to which an entity has a right to invoice. The performance obligation is satisfied when the services are transferred to the customer which the Company determined to be monthly, as the customer simultaneously receives and consumes the benefit from the Company’s performance. Interchange fees are earned when customer-issued cards are processed through card payment networks as the nature of our promise to the customer is that we stand ready to process transactions at the customer’s requests on a daily basis over the contract term. Since the timing and quantity of transactions to be processed by us are not determinable, we view interchange fees to comprise an obligation to stand ready to process as many transactions as the customer requests. Accordingly, the promise to stand ready is accounted for as a single series performance obligation. The Company uses the right to invoice practical expedient and recognizes interchange fee revenue concurrent with the processing of card transactions. Interchange fees are settled in accordance with the card payment network terms and conditions, which is typically within a few days.

The Company utilizes the remote method of revenue recognition for settlement income whereby the unspent balances will be recognized as revenue at the expiration of the cards and the respective program. This has historically been associated with the pharma prepaid business which ended in 2022. The Company records all revenue on a gross basis since it is the primary obligor and establishes the price in the contract arrangement with its customers. The Company is currently under no obligation to refund any fees, and the Company does not currently have any obligations for disputed claim settlements. Given the nature of the Company’s services and contracts, generally it has no contract assets.

Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, customer service, program management, application integration setup, and sales and commission expense. 

Operating Leases – The Company determines if a contract is or contains a leasing element at contract inception or the date in which a modification of an existing contract occurs. In order for a contract to be considered a lease, the contract must transfer the right to control the use of an identified asset for a period of time in exchange for consideration. Control is determined to have occurred if the lessee has the right to (i) obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use and (ii) direct the use of the identified asset.

In determining the present value of lease payments at lease commencement date, the Company utilizes its incremental borrowing rate based on the information available, unless the rate implicit in the lease is readily determinable. The liability for operating leases is based on the present value of future lease payments. Operating lease expenses are recorded as rent expense, which is included within selling, general and administrative expenses within the consolidated statements of operations and presented as operating cash outflows within the consolidated statements of cash flows.

 9 

 

Reclassification

Leases with an initial term of prior year presentation - Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect12 months or less are not recorded on the reported results of operations or cash flows. Duringbalance sheet, with lease expenses for these leases recognized on a straight-line basis over the first quarter of 2017, the Company concluded that it was appropriate to reclassify its customer service center costs from general and administration expense to cost of sales for the three and nine months ended September 30, 2016. In the second quarter of 2017, the company concluded that it was appropriate to reclassify stock payable from liabilities to additional paid in capital for the three and nine month period ended September 30, 2017. These changes in classification does not affect previously reported cash flows from operations in the Consolidated Statement of Cash Flows, and had no effect on the previously reported net income of the Consolidated Statement of Income for any period.lease term.

 

Recent Accounting PronouncementsStock-Based CompensationIn November 2016,The Company recognizes compensation expense for all restricted stock awards and stock options. The fair value of restricted stock awards is measured using the FASB issued Accounting Standards Update 2016-18, “Statementgrant date trading price of Cash Flows – Restricted Cashour stock. The fair value of stock options is estimated at the grant date using the Black-Scholes option-pricing model, and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. We have elected to recognize compensation expense for all options with graded vesting on a consensusstraight-line basis over the vesting period of the FASB Emerging Issues Task Force.” This standard requires restricted cashentire option. The determination of fair value using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and cash equivalents to be included with cashsubjective variables, including expected stock price volatility and cash equivalents on the statement of cash flows under a retrospective transition approach. The guidance became effective for fiscal years beginning December 15, 2017 and interim periods within those fiscal years. The Company has retrospectively adopted ASU 2016-18.risk-free interest rate.

 

Recently Adopted Accounting PronouncementsIn May 2014,June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments–Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides updated guidance on how an entity should measure credit losses on all financial instruments carried at amortized cost (including loans held for investment and held-to-maturity debt securities, as well as trade receivables, reinsurance recoverables, and receivables that relate to repurchase agreements and securities lending agreements), a lessor’s net investments in leases, and off-balance sheet credit exposures not accounted for as insurance or as derivatives, including loan commitments, standby letters of credit, and financial guarantees. Subsequently, in November 2018 the FASB issued ASU No. 2014-09,2018-19, RevenueCodification Improvements to Topic 326, Financial Instruments–Credit Losses, which clarified that receivables arising from Contracts with Customers (Topic 606)("ASU 2014-09"), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or servicesoperating leases are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be requirednot within the revenue recognition process than are required under existing GAAP. ASU 2014-09, as amended by ASU 2015-14,Revenue from Contractsscope of Subtopic 326-20, but instead should be accounted for in accordance with Customers (Topic 606): Deferral of the Effective Date, is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods, with early adoption permitted for annual reporting periods beginning after December 15, 2016. The FASB has also issued a number of additional technical corrections since the initial ASU, all of which follow the effective dates of the new revenue recognition guidance under Topic 606. The amendment allows companies to use either a full retrospective or a modified retrospective approach to adopt this ASU. We have formed a project team and are currently assessing the impact of the adoption of this principle on our consolidated financial statements. We anticipate adopting this ASU on January 1, 2018 using the modified retrospective approach, however, may opt for the full retrospective method depending on the final outcome of our evaluation.

842, Leases. In February 2016,March 2022 the FASB issued Accounting Standards UpdateASU No. 2016-02, Leases.2022-02, Financial Instruments—Credit Losses: Troubled Debt Restructurings and Vintage Disclosures which clarified accounting treatment required for trouble debt restructurings by creditors and enhanced disclosures for write-offs. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard isrelated amendments are effective for fiscal years beginning after December 15, 2018,2022, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Management is currently assessing theWe adopted this guidance; however, there was no material impact of this pronouncementadoption on the Company’s consolidated financial statements.position, results of operations, or cash flows.

 

2.     FIXED ASSETS, NET

 

Fixed assets consist of the following:

Schedule of fixed assets        
 September 30,
2017
 December 31,
2016
  June 30,
2023
  December 31,
2022
 
Equipment $1,343,717  $746,117  $2,241,935  $2,161,424 
Software  120,795   117,163   331,852   327,452 
Furniture and fixtures  119,550   107,141   757,662   757,661 
Website Costs  21,117    
Website costs  69,881   69,881 
Leasehold improvements  50,999   36,499   229,772   229,772 
  1,656,178   1,006,920   3,631,102   3,546,190 
Less: accumulated depreciation  (804,042)  (706,159)  2,506,860   2,290,898 
Fixed assets, net $852,136  $300,761  $1,124,242  $1,255,292 

 

Fixed assets are depreciated over their useful lives ranging from periods of 3 to 7 years.Depreciation expense for the three months ended June 30, 2023 and 2022 was $107,615 and $134,253, respectively. Depreciation expense for the six months ended June 30, 2023 and 2022 was $215,961 and $270,222, respectively.

 

 

 

 10 

 

3.     INTANGIBLE ASSETS, NET

  

Intangible assets consist of the following:

Schedule of intangible assets        
 September 30,
2017
 December 31,
2016
  

June 30,

2023

  December 31,
2022
 
Patents and trademarks $34,940  $34,771  $38,186  $38,186 
Platform and licenses  2,602,924   2,008,307 
Kiosk development  64,802   64,802 
Platform  16,571,814   13,656,014 
Customer lists and contracts  1,177,200   1,177,200 
Licenses  389,165   382,414   209,282   209,282 
Hosting implementation  43,400    
Contract assets  150,000   185,000 
  3,091,831   2,490,294   18,189,882   15,265,682 
Less: accumulated amortization  (1,567,768)  (940,250)  11,191,155   9,608,960 
Intangible assets, net $1,524,063  $1,550,044  $6,998,727  $5,656,722 

 

Intangible assets are amortized over their useful lives ranging from periods of 3 to 5 years.15 years. Amortization expense for the three months ended June 30, 2023 and 2022 was $850,386 and $578,927, respectively. Amortization expense for the six months ended June 30, 2023 and 2022 was $1,587,056 and $1,122,129, respectively.

 

4.     NOTES PAYABLELEASE

 

Notes payable consistThe Company entered into an operating lease for office space which became effective in June 2020. The lease term is 10 years from the effective date and allows for two optional extensions of five years each. The two optional extensions are not recognized as part of the following:

  September 30,
2017
  December 31,
2016
 
Note payable due to a shareholder of the Company, bearing fixed interest at 8%, at December 31, 2016  due on demand and unsecured. $  $102,613 
Notes payable due to various equipment finance companies bearing interest from 12.89% to 15.14% at December 31, 2016.     49,447 
      152,060 
Less: current portion     (124,168)
Notes payable – long term portion $  $27,892 

5.     COMMON STOCKright-of-use asset or lease liability since it is not reasonably certain that the Company will extend this lease. As of June 30, 2023, the remaining lease term was 6.91 years and the discount rate was 6%.

 

At SeptemberOperating lease cost included in selling, general and administrative expenses was $196,214 and $379,435 for the three and six months ended June 30, 2017,2023, respectively. Operating lease cost included in selling, general and administrative expenses was $184,329 and $367,550 for the Company's authorized capital stock was 150,000,000 shares of common stock, par value $0.001 per share,three and 10,000,000 shares of preferred stock, par value $0.001 per share. On that date, the Company had outstanding 43,660,765 shares of common stock, and no shares of preferred stock.six months ended June 30, 2022, respectively.

 

2017 Transactions: DuringThe following is the nine months ended Septemberlease maturity analysis of our operating lease as of June 30, 2017, the Company issued shares of common stock as follows:2023:

 

·

75,000 shares of common stock for current services rendered totaling $12,882 or $0.17 per share (average cost).

·200,000 shares of common stock issued to an employee as a bonus totaling $84,400 or $0.42 per share (average cost)
·200,000 shares of common stock were issued related to exercise of a warrant with an exercise price of $0.25 for a total of $50,000 in cash proceeds.

Year ending December 31,

Schedule of operating lease maturities    
2023 (excluding the six months ended June 30, 2023) $285,984 
2024  571,968 
2025  612,006 
2026  640,604 
2027  640,604 
Thereafter  1,548,127 
Total lease payments  4,299,293 
Less: Imputed interest  (804,108)
Present value of future lease payments  3,495,185 
Less: current portion of lease liability  (372,387)
Long-term portion of lease liability $3,122,798 

 

 

 

 11 

 

2016 Transactions: During5.     CUSTOMER CARD FUNDING LIABILITY

The Company issues prepaid cards with various provisions for cardholder fees or expiration. Revenue generated from cardholder transactions and interchange fees are recognized when the nineCompany’s performance obligation is fulfilled. Unspent balances left on pharma cards are recognized as settlement income at the expiration of the cards and the program. Contract liabilities related to prepaid cards represent funds on card and client funds held to be loaded to card before the amounts are ultimately spent by the cardholders or recognized as revenue by the Company. Contract liabilities related to prepaid cards are reported as Customer card funding liability on the condensed consolidated balance sheet.

The opening and closing balances of the Company's contract liabilities are as follows:

Schedule of contract liabilities      
  

Six Months Ended

June 30,

 
  2023  2022 
Beginning balance $80,189,113  $61,283,914 
Decrease, net  (1,823,268)  15,683,936 
Ending balance $78,365,845  $76,967,850 

The amount of revenue recognized during the six months ended SeptemberJune 30, 2016,2023 and 2022 that was included in the Company issuedopening contract liability for prepaid cards was $2,020,224 and $1,485,005 respectively.

6.     COMMON STOCK

At June 30, 2023, the Company's authorized capital stock was 150,000,000 shares of common stock, as follows:

·437,500 shares of common stock for current services rendered and prior services which had previously been recorded as accrued liability totaling $98,810 or $0.23par value $0.001 per share, (average cost).

Stock and Warrant Grants:25,000,000 shares of preferred stock, par value $0.001 per share. On that date, the Company had 52,842,382 shares of common stock issued and 52,219,374 shares of common stock outstanding, and no shares of preferred stock outstanding.

 

In July 2017 theStock-based compensation expense related to Company granted 200,000 shares of restricted common stock to an employee of the Company with a total value of $84,400 or $0.422 per share. These shares have been issued. Concurrently, the Company also granted the employee four equal tranches of 200,000 restricted common shares, each valued at $84,400 which will vest in equal amounts over a four year period on the last day of each quarter, commencing December 31, 2017. None of these shares have been issued.

In November 2016, the Company granted a total of 5,000,000 shares to certain officers and directors of the Company with a total value of $787,950 or $0.15759 per share (including a 15% discount of fair market value due to these shares being restricted and lacking market liquidity). The 5,000,000 shares have a quarterly vesting period of five years with the first vesting period occurring on December 31, 2016. The approximate value vestedgrants for the three and ninesix months ended SeptemberJune 30, 20172023 was $39,397 $830,426 and $118,191$1,448,670, respectively. As of September 30, 2017, none of the shares have been issued.

In November 2016, the Company granted 210,000 shares to a consultant. The shares were valued at $33,094 or $0.15759 per share (including a 15% discount of fair market value due to these shares being restricted and lacking market liquidity). The 210,000 shares have a quarterly vesting period of three years with the first vesting period occurring on December 31, 2016. The approximate value vestedStock-based compensation expense for the three and ninesix months ended SeptemberJune 30, 20172022 was $2,758$488,287 and $8,274,$1,057,789, respectively. The approximate value vested for 2016 is $2,758. As of September 30, 2017, none of the shares have been issued.

 

In March 2015,2023 Transactions: During the three and six months ended June 30, 2023 the Company granted 200,000issued 74,000 and 192,000 shares of common stock along with 200,000 warrants tofor vested stock awards and the exercise of stock options. The Company received proceeds of $9,600 for the exercise of stock options.

During the three and six months ended June 30, 2023 the Company repurchased 119,558 and 319,558 shares of its common stock at a consultant. The shares were valued at $30,600cost of $311,649 or $0.16weighted average price of $2.61 and $977,667 or weighted average price of $3.06 per share, (including a 15% discount of fair market value due to these shares beingrespectively.

The Company also granted 80,000 and 350,000 restricted and lacking market liquidity). The warrants were valued at $34,611, usingstock awards during the Black-Scholes options pricing model under the following assumptions: stock price at issuance of $0.18 per share; exercise price of $0.50, 3 year life; discount rate of 2.00%;three and volatility rate of 245%. The 200,000 shares and 200,000 warrants granted have a vesting period of six months and were fully vested as of March 31, 2016. As of March 31, 2017, the 200,000 shares have been issued and the warrants for 200,000 shares were granted.ended June 30, 2023.

 

In August 2014,2022 Transactions: During the three and six months ended June 30, 2022 the Company granted 150,000issued 105,000 and 228,000 shares, respectively, of common stock to a consultant with a total valuefor vested stock awards and received proceeds of $25,500 or $0.17 per share (including a 15% discount of fair market value due to these shares being$0 and $0, respectively.

The Company also granted 0 and 100,000 restricted and lacking market liquidity). The 150,000 shares granted have a vesting period of three years and is fully vested as of September 30, 2017. The approximate value vested forstock awards during the three and ninesix months ended SeptemberJune 30, 2017 and 2016 was $2,100, and $6,300, respectively. As of September 30, 2017, 100,000 shares granted have been issued.

In September 2014, the Company granted 150,000 shares of common stock along with 150,000 Class A warrants and 150,000 Class B warrants to an advisory board member. The shares were valued at $19,250 or $0.13 per share (including a 15% discount of fair market value due to these shares being restricted and lacking market liquidity. The warrants were valued at $42,761, using the Black-Scholes options pricing model under the following assumptions: stock price at issuance of $0.15 per share; exercise price of $0.25 for the Class A warrants and $0.50 for the Class B warrants; 3 year life; discount rate of 2.00%; and volatility rate of 245%. The 150,000 shares and 300,000 warrants granted vest over a 3 year period, at 50,000 shares and 100,000 warrants per year of which thirty-six months had vested as of September 30, 2017. The approximate value vested for the three months ended September 30, 2017 and 2016 $5,100 respectively and for the nine months ended September 30, 2017 and 2016 was $14,200 and $15,300, respectively. As of September 30, 2017, all of the 150,000 shares were issued and the 300,000 warrants granted have expired.

In September 2014, the Company granted 200,000 shares of common stock along with 200,000 warrants to a consultant. The shares were valued at $30,600 or $0.16 per share (including a 15% discount of fair market value due to these shares being restricted and lacking market liquidity). The warrants were valued at $34,611, using the Black-Scholes options pricing model under the following assumptions: stock price at issuance of $0.18 per share; exercise price of $0.25; 3 year life; discount rate of 2.00%; and volatility rate of 245%. The 200,000 shares and 200,000 warrants granted had a vesting period of nine months and were fully vested as March 31, 2015. During the three months ended March 31, 2016 the company had issued the 200,000 shares and warrant for 200,000 shares of common stock. As of September 30, 2017, warrants relating to 200,000 shares have been exercised for total proceeds of $50,000.2022.

 

 

 

 12 

 

In October 2014, the Company granted 150,000 shares of common stock to an advisory board member with a total value of $32,400 or $0.21 per share (including a 10% discount of fair market value due to these shares being restricted and lacking market liquidity). The 150,000 shares granted will vest over a 3 year period, at 50,000 shares per year and is fully vested as of September 30, 2017. The approximate value vested for the three months and nine months ended September 30, 2017 and 2016 was $2,700 and $8,100, respectively. As of September 30, 2017, all 150,000 of the shares have been issued.7.     BASIC AND FULLY DILUTED NET LOSS PER COMMON SHARE

 

In November 2014,The following table sets forth the Company issued a warrant for 100,000 sharescomputation of basic and fully diluted net loss per common stock as part of an issuance of note payable totaling $100,000. The warrant has an exercise price of $0.50 per share and life of three years.

In October 2013, the Company granted 300,000 shares of common stock to an employee of the Company with a total value of $38,250 or $0.15 per share (including a 15% discount of fair market value due to these shares being restricted and lacking market liquidity). The 300,000 shares granted have a vesting period of three years and was fully vested as of October 2016. The approximate value vested for the three and ninesix months ended SeptemberJune 30, 20172023 and 20162022:

Schedule of computation of earnings per share            
  Three Months Ended June 30,  Six Months Ended June 30, 
  2023  2022  2023  2022 
Numerator:                
Net loss $(104,156) $(228,034) $(264,286) $(537,429)
Denominator:                
Weighted average common shares:                
Denominator for basic calculation  52,259,002   51,993,031   52,330,829   51,906,335 
Weighted average effects of potentially diluted common stock:                
Stock options (calculated using the treasury method)            
Unvested restricted stock grants            
Denominator for fully diluted calculation  52,259,002   51,993,031   52,330,829   51,906,335 
Net loss per common share:                
Basic $(0.00) $(0.00) $(0.01) $(0.01)
Fully diluted $(0.00) $(0.00) $(0.01) $(0.01)
                 
Anti-dilutive shares:                
Stock options  1,815,000   1,884,400   1,815,000   1,884,400 
Unvested restricted stock options  3,652,000   1,064,000   3,652,000   1,064,000 

The potential common share equivalents are not added to the denominator for three and six months ended June 30, 2023 and 2022 because the inclusion was $0.00anti-dilutive, and $3,200, respectively. Astherefore, all such shares were excluded from the computation of March 31, 2017, all 300,000diluted weighted average shares granted have been issued.outstanding for both periods.

 

6.     LEGAL SETTLEMENT PAYABLE8.     COMMITMENTS AND CONTINGENCIES

 

On August 11, 2015, PSKW, LLC (“PSKW”) servedFrom time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

The Company withhas been named as a complaint titledPSKW, LLC v. 3Pea International, Inc.,defendant in three complaints filed in the United States District Court for the Northern District of California, Case No. 5:15-cv-03576-RMW, San Jose Division (the “Action”Nevada: Yilan Shi v. Paysign, Inc. et. al., filed on March 19, 2020 (“Shi”), Lorna Chase v. Paysign, Inc. et. al., filed on March 25, 2020 (“Chase”), and Smith & Duvall v. Paysign, Inc. et. al., filed on April 2, 2020 (collectively, the “Complaints” or “Securities Class Action”). InSmith & Duvall v. Paysign, Inc. et. al. was voluntarily dismissed on May 21, 2020. On May 18, 2020, the Action, PSKW asserted claims againstShi plaintiffs and another entity called the Paysign Investor Group each filed a motion to consolidate the remaining Shi and Chase actions and to be appointed lead plaintiff. The Complaints are putative class actions filed on behalf of a class of persons who acquired the Company’s common stock from March 19, 2019 through March 31, 2020, inclusive. The Complaints generally allege that the Company, for $5,800,000 for marketing fees allegedly due by the Company. The Company contended, among other things, that PSKW breached its agreement with the Company, for which the Company was damaged in an amount in excessMark R. Newcomer, and Mark Attinger violated Section 10(b) of the amount which PSKW claimed was owed by the Company to PSKW. The parties each denied liability,Exchange Act, and entered into a Settlement Agreementthat Messrs. Newcomer and Release on October 2, 2015 whereby the Company agreed to pay $2,500,000 to PSKW in full settlementAttinger violated Section 20(a) of the Action.Exchange Act, by making materially false or misleading statements, or failing to disclose material facts, regarding the Company’s internal control over financial reporting and its financial statements. The settlement amount was payable byComplaints seek class action certification, compensatory damages, and attorney’s fees and costs. On December 2, 2020, the Court consolidated Shi and Chase as In re Paysign, Inc. Securities Litigation and appointed the Paysign Investor Group as lead plaintiff. On January 12, 2021, Plaintiffs filed an initial payment of $1,000,000Amended Complaint in the consolidated action. Defendants filed a Motion to Dismiss the Amended Complaint on March 15, 2021, which was paidPlaintiffs opposed via an opposition brief filed on April 29, 2021, to which Defendants replied on June 1, 2021. On February 9, 2023, the Court granted in October 2015, with the balance of $1,500,000 being payablepart and denied in equal monthly installments over 18 months with interest at 3% per annum commencing on November 1, 2015. The Court dismissed the Action with prejudice, but retained jurisdictionpart Defendants’ Motion to enforce the Settlement Agreement. 3Pea Technologies, Inc., a wholly-owned subsidiary of the Company, guaranteed the amount due under the Settlement Agreement. The Company expensed the entire $2,500,000 settlement during the year ended December 31, 2015 since the principal terms of the Settlement Agreement had been agreed to as of that date.Dismiss. As of March 31, 2017, the settlement was paid in full.

7.    SUBSEQUENT EVENTS

There were no reportable subsequent events after September 30, 2017 through the date of this filing.filing, the Company cannot give any meaningful estimate of likely outcome or damages.

 

 

 

 13 

The Company has also been named as a nominal defendant in two stockholder derivative actions in the United States District Court for the District of Nevada. The first derivative action is entitled Andrzej Toczek, derivatively on behalf of Paysign, Inc. v. Mark R. Newcomer, et al. and was filed on September 17, 2020. This action alleges violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, and waste, largely in connection with the failure to correct information technology controls over financial reporting alleged in the Securities Class Action, thereby causing the Company to face exposure in the Securities Class Action. The complaint also alleges insider trading violations against certain individual defendants. On December 16, 2020, the Court approved a stipulation staying the action until the Court in the consolidated Securities Class Action issues a ruling on the Motion to Dismiss. The second derivative action is entitled John K. Gray, derivatively on behalf of Paysign, Inc. v. Mark Attinger, et al. and was filed on May 9, 2022. This action involves the same alleged conduct raised in the Toczek action and asserts claims for breach of fiduciary duty in connection with financial reporting, breach of fiduciary duty in connection with alleged insider trading against certain individual defendants, and unjust enrichment. On June 3, 2022, the Court approved a stipulation staying the action until the Court in the consolidated Securities Class Action issues a ruling on the Motion to Dismiss. On May 10, 2023, the Toczek and Gray actions were consolidated. The Company anticipates filing motions to dismiss given the ruling on the Motion to Dismiss in the consolidated cases. As of the date of this filing, the Company cannot give any meaningful estimate of likely outcome or damages.

9.     RELATED PARTY

A former member of our Board of Directors who served through December 31, 2022 is also a partner in a law firm that the Company engages for services to review regulatory filings and for various other legal matters. During the three and six months ended June 30, 2022, the Company incurred legal expenses of $41,019 and 81,753, respectively, with the related party law firm.

10.   INCOME TAX

The effective tax rate (income tax provision as a percentage of loss before income tax provision) was (126.3%) for the three months ended June 30, 2023, as compared to (13.4%) for the three months ended June 30, 2022. The effective tax rate was (29.2%) and (5.7%) for the six months ended June 30, 2023 and 2022, respectively. The effective tax rates vary, primarily as a result of the full valuation on our deferred tax asset in the current year and the tax benefit related to our stock-based compensation expense and a pretax loss in the prior year period.

Under the provisions of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) signed into law in 2020 and the subsequent extension of the CARES Act through September 30, 2021, the Company was eligible for a refundable employee retention credit subject to certain criteria. The Company has elected an accounting policy to recognize the government assistance when it is probable that the Company is eligible to receive the assistance and present the credit as a reduction of the related expense. As of June 30, 2023 and December 31, 2022, the Company recorded $836,734 and $1,296,488, respectively in other receivables on the condensed consolidated balance sheet related to U.S. Federal Government refunds.

14

Item 2. Management’s discussion and analysis of financial condition and results of operations.

Disclosure Regarding Forward LookingForward-Looking Statements

This Quarterly Report on Form 10-Q includes forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Forward LookingForward-Looking Statements”). All statements other than statements of historical fact included in this report are Forward LookingForward-Looking Statements. These Forward-Looking Statements are based on our current expectations, assumptions, estimates and projections about our business and our industry. Words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “propose,” “may,” and other similar expressions identify Forward-Looking statements. In the normal course of our business, we, in an effort to help keep our shareholders and the public informed about our operations, may from time-to-time issue certain statements, either in writing or orally, that containscontain, or may contain, Forward-Looking Statements. Although we believe that the expectations reflected in such Forward-Looking Statements are reasonable, we can give no assurance that such expectations will prove to have been correct. Generally, theseIn addition, any statements relatethat refer to business plans or strategies, projected or anticipated benefitsexpectations, projections, estimates, forecasts, or other consequencescharacterizations of such plansfuture events or strategies, past and possible future, of acquisitions and projected or anticipated benefits from acquisitions made by or to be made by us, or projections involving anticipated revenues, earnings, levels of capital expenditures or other aspects of operating results. All phases of our operationscircumstances are Forward-Looking Statements. These Forward-Looking Statements are subject to a number of uncertainties,certain risks and other influences, many of which are outside of our control and any one of which, or a combination of which,uncertainties that could cause actual results to differ materially affectfrom those reflected in the results of our proposed operations and whether Forward Looking Statements made by us ultimately prove to be accurate.Forward-Looking Statements. Such important factors (“Important Factors”) and other factors could cause actual results to differ materially from our expectations are disclosed in this report, including those factors discussed in “Item“Part II - Item 1A. Risk Factors.” All prior and subsequent written and oral Forward LookingForward-Looking Statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the Important Factors described below that could cause actual results to differ materially from our expectations as set forth in any Forward LookingForward-Looking Statement made by or on behalf of us. You are cautioned not to place undue reliance on these Forward-Looking Statements, which relate only to events as of the date on which the statements are made. We undertake no obligation to publicly revise these Forward-Looking Statements to reflect events or circumstances that arise after the date hereof. You should refer to and carefully review the information in future documents we file with the Securities and Exchange Commission.

Overview

 

Overview

3PEA International,Paysign, Inc. is(the “Company,” “Paysign,” “we” or “our”), headquartered in Nevada, was incorporated on August 24, 1995, and trades under the symbol PAYS on The Nasdaq Stock Market LLC. We are a vertically integrated provider of innovative prepaid card programsproducts and processing services for corporate, consumer and government applications. Our payment solutions are utilized by our corporate customers as a means to increase customer loyalty, increase patient adherence rates, reduce administration costs and streamline operations. Public sector organizations can utilize theour payment solutions to disburse public benefits or for internal payments. We market our prepaid debit card solutions under our PaySignPaysign® brand. As we are a payment processor and debitprepaid card program manager, we derive our revenue from all stages of the debitprepaid card lifecycle.

We operate on a powerful, high-availability payments platform with cutting-edge fintech capabilities that can be seamlessly integrated with our clients’ systems. This distinctive positioning allows us to provide a card processing platform consisting of proprietary systems and innovative software applications based on the unique needs of our programs. We have extended our processing business capabilities through our proprietary PaySign platform. Through the PaySign platform, we provide a variety of services includingend-to-end technologies that securely manage transaction processing, cardholder enrollment, value loading, cardholder account management, reporting,data and analytics, and customer service. Our architecture is known for its cross-platform compatibility, flexibility, and scalability – allowing our clients and partners to leverage these advantages for cost savings and revenue opportunities.

 

The PaySign platform was built on modern cross-platform architecture and designed to be highly flexible, scalable and customizable. The platform has allowed 3PEA to significantly expand its operational capabilities by facilitating our entry into new markets within the payments space through its flexibility and easeOur suite of customization. The PaySign platform delivers cost benefits and revenue building opportunities to our partners.

We have developed prepaid card programsproduct offerings include solutions for corporate and incentive rewards, including, but not limited toprepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical co-paypayment assistance, donor compensation and automobile dealership incentives. We are expandingdemand deposit accounts accessible with a debit card. In the future, we expect to further expand our product offering to include additional corporate incentive products, payroll cards, general purpose re-loadable cards,into other prepaid card offerings such as travel cards and expense reimbursement cards. Our cards are offered to end users throughsponsored by our relationships withissuing bank issuers.partners.

 

We are a vertically integrated payment processor and debitOur revenues include fees generated from cardholder fees, interchange, card program manager offering innovative payment solutions to corporations, government agencies, universitiesmanagement fees, transaction claims processing fees, and other organizations. Our payment solutions are utilized by our customers as a means to increase customer loyalty, reduce administration costs and streamline operations. We market our prepaid debit card solutions under our PaySign brand. As we are a payment processor and debitsettlement income. Revenue from cardholder fees, interchange, card program manager, we derive our revenue from all stagesmanagement fees, and transaction claims processing fees is recorded when the performance obligation is fulfilled. Settlement income is recorded at the expiration of the debit card lifecycle. These revenues can include fees from program set-up; customization and development; data processing and report generation; card production and fulfillment; transaction fees derived from card usage; inactivity fees; card replacement fees and program administration fees. We provide an in-house customer service centerrelates solely to our pharma prepaid business which includes live bi-lingual phone operators staffed 24/7, for incoming calls. We also provideended in house Interactive Voice Response (IVR), SMS alerts and two way SMS messaging platforms.2022.

 

 

 

 1415 

 

We are a vertically integrated payment processor and debit card program manager offering innovative payment solutions to corporations, government agencies, universities and other organizations. Our payment solutions are utilized by our customers as a means to increase customer loyalty, reduce administration costs and streamline operations. We markethave two categories for our prepaid debit card solutions under our PaySign brand. As we are a payment processor and debit card program manager, we derive our revenue from all stages of the debit card lifecycle. These revenues can include fees from program set-up; customization and development; data processing and report generation; card production and fulfillment; transaction fees derived from card usage; inactivity fees; card replacement fees and program administration fees. We provide an in-house customer service center which includes live bi-lingual phone operators staffed 24/7, for incoming calls. We also provide in house Interactive Voice Response and two way SMS messaging platforms.

The Company divides prepaid cards into two general categories:cards: (1) corporate and consumer reloadable cards, and (2) non-reloadable cards.

 

Reloadable Cards: These types of cards are generally incentive,classified as payroll or considered general purpose reloadable (“GPR”) cards. Payroll cards are issued to an employee by an employer to receivean employee in order to allow the direct deposit ofemployee to access payroll amounts that are deposited into an account linked to their payroll.card. GPR cards can also be issued to a consumer at a retail location or mailed to a consumer after completing an on-line application. GPR cards can be reloaded multiple times with a consumer’s payroll, government benefit, a federal or state tax refund or through cash reload networks located at retail locations. Reloadable cards are generally open loopopen-loop cards as described below.

 

Non-Reloadable Cards: These are generally one-time use cards that are only active until the funds initially loaded to the card are spent. These types of cards are generally used as gift or incentive cards. These cards may be open loop or closed loop. Normally these types of cards are used for the purchase of goods or services at retail locations and cannot be used to receive cash.

 

These prepaidBoth reloadable and non-reloadable cards may be open loop, closed loopopen-loop, closed-loop, or semi-closed loop. Open looprestricted-loop. Open-loop cards can be used to receive cash at ATM locations by PIN; or purchase goods or services by PIN or signature at retail locations. These cards can be usedlocations virtually anywhere that the network brand (Visa, MasterCard,(American Express, Discover, Mastercard, Visa, etc.) is accepted. Closed loopClosed-loop cards can only be used at a specific merchant. Semi-closed loopRestricted-loop cards can be used at several merchants, or a defined group of merchants, such as all merchants at a specific shopping mall.

 

The prepaid card market is one of the fastest growing segments of the payments industry in the U.S. This market has experienced significant growth in recent years due to consumers and merchants embracing improved technology, greater convenience, more product choices and greater flexibility. Prepaid cards have also proven to be an attractive alternative to traditional bank accounts for certain segments of the population, particularly those without, or who could not qualify for, a checking or savings account.

 

We have developed prepaid card programs for healthcare reimbursement payments, corporate and incentive rewards and expense reimbursement cards. We plan to expand our product offering to include payroll cards, general purpose re-loadable cards and travel cards. Our cards are offered to end users through our relationships with bank issuers.

Our products and services are aimed at capitalizing on the growing demand for stored value and reloadable ATM/prepaid card financial products in a variety of market niches. Our proprietary platform is scalable and customizable, delivering cost benefits and revenue building opportunities to partners. We manage all aspects of the debitprepaid card lifecycle, from managing the card design and approval processes with banking partners and card associations,networks, to production, packaging, distribution, and personalization. We also oversee inventory and security controls, renewals, lost and stolen card management, and replacement. We deploy a 24/7/365 fully staffed, in-house customer service department which utilizes bilingual customer service representatives, Interactive Voice Response, and two-way short message service messaging and text alerts.

Currently, we are focusing our marketing efforts on corporate incentive and expense prepaid card products in various market verticals including but not limited to general corporate expense, healthcare related markets including patient affordability solutions, clinical trials and donor compensation, loyalty rewards, and incentive cards.

 

As part of our continuing platform expansion development process, we evaluate current and emerging technologies for applicability to our existing and future software platform. To this end, we engage with various hardware and software vendors in evaluation of various infrastructure components. Where appropriate, we use third-party technology components in the development of our software applications and service offerings. Third-party software may be used for highly specialized business functions, which we may not be able to develop internally within time and budget constraints. Our principal target markets for processing services include prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and in emerging international markets.Mexico.

 

The Company is devotingWe have devoted more extensive resources to sales and marketing activities as we have added essential personnel to our marketing, sales and support teams. We market our Paysign payment solutions through direct marketing by the Company’s sales department.team. Our primary market focus is on companies that require a streamlined payment solution for rewards, rebates, payment assistance, and other payments to their customers, employees, agents and others. To reach these markets, we focus our sales efforts on direct contact with our target market and attendance at various industry specific conferences. We sellmay, at times, utilize independent contractors who make direct sales and are paid commissions and/or restricted stock awards. We market our products directlyPaysign Premier product through existing communication channels to customers in the U.S. but may worka targeted segment of our existing cardholders, as well as to a broad group of individuals, ranging from non-banked to fully banked consumers with a small numberfocus on long term users of resellers and third parties in international markets to identify, sell and support targeted opportunities.

our product.

 

 

 

 1516 

 

In orderFor the remainder of 2023, we plan to expand into new markets, we will needcontinue to invest additional funds in technology improvements, sales and marketing, expenses,customer service, and regulatory compliance costs. We are consideringcompliance. From time to time, we evaluate raising capital to enable us to diversify into new market verticals. If we do not raise new capital, we believe that we will still be able to support our existing business and expand into new vertical markets using internally generated funds, but our expansion will not be as rapid.funds.

 

Results of Operations

 

Comparison of the Three Months ended SeptemberEnded June 30, 2017 and 20162023 to the Three Months Ended June 30, 2022

RevenuesThe following table summarizes our consolidated financial results for the three months ended SeptemberJune 30, 2017 were $4,001,991, an2023 in comparison to the three months ended June 30, 2022:

  

Three Months Ended

June 30,

(Unaudited)

  Variance 
  2023  2022  $  % 
Revenues                
Plasma industry $10,014,461  $7,806,201  $2,208,260   28.3% 
Pharma industry  729,236   773,311   (44,075)  (5.7%)
Other  297,354   19,264   278,090   1443.6% 
Total revenues  11,041,051   8,598,776   2,442,275   28.4% 
Cost of revenues  5,425,311   3,900,965   1,524,346   39.1% 
Gross profit  5,615,740   4,697,811   917,929   19.5% 
Gross margin %  50.9%   54.6%         
                 
Operating expenses                
Selling, general and administrative  5,304,625   4,255,976   1,048,649   24.6% 
Depreciation and amortization  958,001   713,180   244,821   34.3% 
Total operating expenses  6,262,626   4,969,156   1,293,470   26.0% 
Loss from operations $(646,886) $(271,345) $(375,541)  138.4% 
                 
Net loss $(104,156) $(228,034) $123,878   (54.3%)
Net margin %  (0.9%)  (2.7%)        

The increase in total revenues of $1,189,455$2,442,275 for the three months ended June 30, 2023 compared to the same period in the prior year when revenues were $2,812,536.consisted primarily of a $2,208,260 increase in Plasma revenue, a $44,075 decrease in Pharma revenue, and a $278,090 increase in Other revenue. The increase in Plasma revenue iswas primarily due to an increase in the number of plasma centers and donations, and, consequently, dollars loaded to cards, cardholder fees, and interchange, as there continues to be an increase in demand for plasma driven by global increases of plasma protein therapies. The decrease in Pharma revenue was primarily due to the end of our pharma prepaid programs in 2022, offset by the launch of new corporate incentivepharma patient affordability programs. The increase in Other revenue was primarily due to the launch of new payroll, retail programs, and other prepaid card products and growth within our existing corporate incentive prepaid card products. However, our revenue during this period was slightly impacted by diminished card usage in areas affected by hurricanes in Texas and Florida. As of September 30, 2017, we managed 175 card programs with over 1,390,000 participating cardholders.disbursement programs.

 

The Company expects revenues to continue to trend upwards for the foreseeable future as we expect to onboard over 35 additional corporate incentive card programs in the fourth quarter of 2017.

 

17

Cost of revenues for the three months ended SeptemberJune 30, 2017 were $2,145,621, an increase of $623,1632023 increased $1,524,346 compared to the same period in the prior year, when cost of revenues was $1,522,458. Cost of revenues constituted approximately 54% and 54% of total revenues in the same quarter 2017 and 2016, respectively. Although cost of revenues remained relatively constant when compared to the same period in the previous year, cost of revenue in the period ended September 30, 2017 was impacted by costs associated with program set up and launch.year. Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, customer service, and program management, expenses, application integration setup, and sales and commission expense. Cost of revenues increased during the second quarter of 2023 primarily due to an increase in cardholder usage activity and associated network expenses such as interchange and ATM costs, an increase in plastics and collateral related to an increase in the number of unique card loads, an increase in network expenses and sales commissions related to the growth in our pharma patient affordability business, a new direct network connection with Mastercard, and an increase in customer service expenses associated with wage inflation pressures and the overall growth in our business, offset by a decline in postage.

 

Gross profit for the three months ended SeptemberJune 30, 2017 was $1,856,370, an increase of $566,2922023 increased $917,929 compared to the same period in the prior year whenresulting primarily from the increase in Plasma revenue and the beneficial impact of a variable cost structure as many of the plasma transaction costs are variable in nature which are provided by third parties who charge us based on the number of active cards outstanding and the number of transactions that occurred during the period. The increase in gross profit was $1,290,078. Our overall gross profit percentage approximated 46%offset by the termination of our pharma prepaid business in 2022, price increases by many of our third party service providers, a new direct network connection with Mastercard, and 46% during the second quarters of 2017 and 2016 which is consistent with our overall expectations.

Depreciation and amortization for the three months ended September 30, 2017 were $276,533, an increase of $127,191 compared to the same period prior year of $149,342. Overall increase in depreciation and amortization was primarily a result of an increase in depreciation related to an increasecustomer service expenses mentioned above. The decrease in capital expenditures and amortization expense related to additional capitalized platform costs.gross margin resulted from the aforementioned factors.

 

Selling, general and administrative expenses (“SG&A”) for the three months ended SeptemberJune 30, 2017 were $1,104,280, an increase of $443,7242023 increased $1,048,649 compared to the same period in the prior year when selling, general and administrative expenses were $660,556. Theconsisted primarily of an increase in selling, generalcompensation and administrative expenses wasbenefits of approximately $690,000 due to increasescontinued hiring to support the Company’s growth, a tight labor market and increased personnel insurance costs, an increase in staff as we experiencedstock based compensation expense of approximately $340,000, and an accelerated rateincrease in non-IT outside professional services of new card product launchesapproximately $235,000. This increase was offset by a $210,000 increase in the second halfamount of 2017.capitalized platform development costs and a decrease in all other operating expenses of approximately $8,000.

 

InDepreciation and amortization expense for the three months ended SeptemberJune 30, 2017, we recorded operating income of $475,557, as2023 increased $244,821 compared to $480,180 in the same period in the prior year,year. The increase in depreciation and amortization expense was primarily due to continued capitalization of new software development costs and equipment purchases related to the continued enhancements to our processing platform.

For the three months ended June 30, 2023, we recorded a loss from operations of $646,886 representing a decrease in operating incomedecline of $(4,623).$375,541 compared to a loss from operations of $271,345 during the same period last year related to the aforementioned factors.

 

Other income (expense) for the three months ended SeptemberJune 30, 2016 was $14,3982023, increased $530,640 primarily related to an increase in interest rates and the associated interest income received on higher bank account balances at our sponsor bank.

We recorded an income tax expense of $58,137 for the three months ended June 30, 2023, which equates to an effective tax rate of (126.3%) primarily as a result of state taxes, the full valuation on our deferred tax asset, the tax benefit related to our stock-based compensation expense and the pretax loss during the period. We recorded an income tax expense of $26,916 for the three months ended June 30, 2022, which equates to an effective tax rate of (13.4%) primarily as a result of the full valuation on our deferred tax asset, the tax benefit related to our stock-based compensation expense and the pretax loss during the period.

The net other income (expense)loss for the three months ended June 30, 2023 was $104,156, an improvement of $29,895$123,878 compared to the net loss of $228,034 for the three months ended June 30, 2022. The overall change in net loss relates to the aforementioned factors.

18

Comparison of the Six Months Ended June 30, 2023 to the Six Months Ended June 30, 2022

The following table summarizes our consolidated financial results for the six months ended June 30, 2023 in comparison to the six months ended June 30, 2022:

  

Six Months Ended

June 30,

(unaudited)

  Variance 
  2023  2022  $  % 
Revenues                
Plasma industry $19,374,528  $15,200,565  $4,173,963   27.5% 
Pharma industry  1,318,798   1,579,879   (261,081)  (16.5%)
Other  491,015   38,971   452,044   1159.9% 
Total revenues  21,184,341   16,819,415   4,364,926   26.0% 
Cost of revenues  10,520,932   7,123,355   3,397,577   47.7% 
Gross profit  10,663,409   9,696,060   967,349   10.0% 
Gross margin %  50.3%   57.6%         
                 
Operating expenses                
Selling, general and administrative  10,250,075   8,896,888   1,353,187   15.2% 
Depreciation and amortization  1,803,017   1,392,351   410,666   29.5% 
Total operating expenses  12,053,092   10,289,239   1,763,853   17.1% 
Loss from operations $(1,389,683) $(593,179) $(796,504)  134.3% 
                 
Net loss $(264,286) $(537,429) $273,143   (50.8%)
Net margin %  (1.2%)  (3.2%)        

The increase in total revenues of $4,364,926 for the six months ended June 30, 2023 compared to the same period in the prior year when other income (expense) was $(15,497) which is within our overall expectations.   

Net income before noncontrolling interest for the three months ended September 30, 2017 was $489,955, anconsisted primarily of a $4,173,963 increase of $25,272 compared to the same period in the prior year of $464,683.Plasma revenue and a $452,044 increase in Other revenue, offset by a $261,081 decrease in Pharma revenue. The increase in our net income before noncontrolling interest is attributable to the aforementioned factors.

Net loss attributable to noncontrolling interest for the three months ended September 30, 2017Plasma revenue was $13,213, a decrease of $2,533 compared to the same period in the prior year of $15,746 The decrease in net loss attributable to noncontrolling interest is primarily due to a decrease in expenses related to our European operations.

16

Net income attributable to 3Pea International, Inc. for the three months ended September 30, 2017 was $500,168, an increase of $19,739 compared to the same period in the prior year, when we recorded net income of $480,429. The increase in our net income is attributable to the aforementioned factors.

Nine Months ended September 30, 2017 and 2016

Revenues for the nine months ended September 30, 2017 were $10,621,055, an increase of $3,251,515 compared to the same period in the prior year, when revenues were $7,369,540. The increase in revenue is primarily due to an increase in the number of plasma centers and donations, and, consequently, dollars loaded to cards, cardholder fees, and interchange, as COVID-19 restrictions such as donation center closures, mobility restrictions and Federal government stimulus measures were relaxed compared to the prior year period. The increase in Other revenue was primarily driven by our new corporate incentivepayroll, retail, and other prepaid card products and growth withindisbursement programs. The decrease in Pharma revenue was primarily due to the end of our existing corporate incentivepharma prepaid card products.programs in 2022, offset by the launch of new pharma patient affordability programs.

 

Cost of revenues for the ninesix months ended SeptemberJune 30, 2017 were $5,834,709, an increase of $1,772,6472023 increased $3,397,577 compared to the same period in the prior year, when cost of revenues was $4,062,062. Cost of revenues constituted approximately 55% and 55% of total revenues in 2017 and 2016, respectively.year. Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, customer service, and program management, expenses, application integration setup, and sales and commission expense. Cost of revenues increased during the six months of 2023 primarily due to the increase in cardholder usage activity and associated network expenses such as interchange and ATM costs, an increase in plastics, collateral and postage expenses related to changes to collateral materials, the increase in network expenses related to our pharma patient affordability business, and the increase in customer service expenses associated with wage inflation pressures and the overall growth in our business, offset by a decline in sales commissions related to the restructuring of an agreement in the first quarter of 2022.

19

 

Gross profit for the ninesix months ended SeptemberJune 30, 2017 was $4,786,346, an increase of $1,478,8682023 increased $967,349 compared to the same period in the prior year whenresulting from the increase in Plasma revenue, the restructuring of an agreement mentioned above, and the beneficial impact of a variable cost structure as many of the plasma transaction costs are provided by third parties who charge us based on the number of transactions that occurred during the period. The increase in gross profit was $3,307,478. Our overall gross profit percentage approximated 45%offset by the termination of our pharma prepaid business in 2022, price increases by many of our third party service providers, a new direct network connection with Mastercard, and 45% during the first nine months of 2017 and 2016 which is consistent with our overall expectations.

Depreciation and amortization for the nine months ended September 30, 2017 were $725,401, an increase of $319,073 compared to the same period prior year of $406,328. Overall increase in depreciation and amortization was primarily a result of an increase in amortization expense related to additional capitalized platform costs.customer service expenses mentioned above. The decrease in gross margin resulted from the aforementioned factors.

 

Selling, general and administrative expensesSG&A for the ninesix months ended SeptemberJune 30, 2017 were $2,847,955, an increase of $793,6042023 increased $1,353,187 compared to the same period in the prior year when selling, general and administrative expenses were $2,054,351. The increase in selling, general and administrative expenses was due to increases in staff in anticipationconsisted primarily of an accelerated rate of new card product launches in the second half of 2017.

In the nine months ended September 30, 2017, we recorded operating income of $1,212,990, as compared to $846,799 in the same period in the prior year, an increase in operating incomecompensation and benefits of $366,191.

Other income (expense) forapproximately $1,688,000 due to continued hiring to support the nine months ended September 30, 2017 was $8,772,Company’s growth, a tight labor market and increased personnel insurance costs, an increase in netstock based compensation expense of approximately $391,000, an increase in outside professional services for non-IT outside professional services of approximately $117,000, and an increase in all other income (expense)operating expenses of $56,620approximately $13,000. This increase was offset by an increase of approximately $856,000 in capitalized platform development costs.

Depreciation and amortization expense for the six months ended June 30, 2023 increased $410,666 compared to the same period in the prior year when other income (expense)year. The increase in depreciation and amortization expense was $(47,848) which is withinprimarily due to continued capitalization of development costs and equipment purchases related to the continued enhancements to our overall expectations.processing platform.

 

Net income before noncontrolling interest forFor the ninesix months ended SeptemberJune 30, 2017 was $1,212,762, an increase2023 we recorded a loss from operations of $413,811$1,389,683 representing a decline of $796,504 compared to the same period in the priorlast year of $798,951. The increase in our net income before noncontrolling interest is attributablerelated to the aforementioned factors.

 

Net loss attributable to noncontrolling interestOther income for the ninesix months ended SeptemberJune 30, 20172023 increased $1,100,501 related to an increase in interest rates and the associated interest income received on higher bank account balances at our sponsor bank.

We recorded an income tax expense of $59,667 for the six months ended June 30, 2023 which equates to an effective tax rate of (29.2%) primarily as a result of the full valuation on our deferred tax asset, the tax benefit related to our stock-based compensation expense and the pretax loss during the period. We recorded an income tax expense of $28,813 for the six months ended June 30, 2022, which equates to an effective tax rate of (5.7%) primarily as a result of the full valuation on our deferred tax asset, the tax benefit related to our stock-based compensation expense and the pretax loss during the period.

The net loss for the six months ended June 30, 2023 was $41,242, a decrease$264,286, an improvement of $(57,855)$273,143 compared to the same period innet loss of $537,429 for the prior year of $99,097.six months ended June 30, 2022. The decreaseoverall change in net loss attributable to noncontrolling interest is primarily due to a decrease in expenses related to our European subsidiary.

Net income attributable to 3Pea International, Inc. for the nine months ended September 30, 2017 was $1,254,004, an increase of $355,956 compared to the same period in the prior year, when we recorded net income of $898,048. The increase in our net income is attributablerelates to the aforementioned factors.

 

Key Performance Indicators and Non-GAAP Measures

Management reviews a number of metrics to help us monitor the performance of and identify trends affecting our business. We believe the following measures are the primary indicators of our quarterly and annual revenues:

Gross Dollar Volume Loaded on Cards – Represents the total dollar volume of funds loaded to all of our prepaid card programs. Our gross dollar volume loaded on cards was $405 million and $375 million for the three months ended June 30, 2023 and 2022, respectively. We use this metric to analyze the total amount of money moving into our prepaid card programs.

20

Conversion Rates on Gross Dollar Volume Loaded on Cards – Equals revenues, gross profit or net loss conversion rates of gross dollar volume loaded on cards which are calculated by taking our total revenues, gross profit or net loss, respectively, as a numerator and dividing by the gross dollar volume loaded on cards as a denominator. As we derive a number of our financial results from cardholder fees, we utilize these metrics as an indication of the amount of money that is added to cards and will eventually be converted to revenues, gross profit and net income (loss). Our total revenue conversion rates for the three months ended June 30, 2023 and 2022 were 2.73% or 273 basis points (“bps”), and 2.29% or 229 bps, respectively, of gross dollar volume loaded on cards. Our total gross profit conversion rates for the three months ended June 30, 2023 and 2022 were 1.39% or 139 bps, and 1.25% or 125 bps, respectively, of gross dollar volume loaded on cards. Our net loss conversion rates for the three months ended June 30, 2023 and 2022 were (0.01%) or (1) bp, and (0.06%) or (6) bps, respectively, of gross dollar volume loaded on cards.

Management also reviews key performance indicators, such as revenues, gross profit, operational expenses as a percent of revenues, and cardholder participation. In addition, we consider certain non-GAAP (or “adjusted”) measures to be useful to management and investors evaluating our operating performance for the periods presented, and provide a financial tool for evaluating our ongoing operations, liquidity and management of assets. This information can assist investors in assessing our financial performance and measures our ability to generate capital for deployment and investment in new card programs. These adjusted metrics are consistent with how management views our business and are used to make financial, operating and planning decisions. These metrics, however, are not measures of financial performance under GAAP and should not be considered a substitute for revenue, operating income, net income (loss), earnings (loss) per share (basic and diluted) or net cash from operating activities as determined in accordance with GAAP. We consider the following non-GAAP measures, which may not be comparable to similarly titled measures reported by other companies, to be key performance indicators:

“EBITDA” is defined as earnings before interest, income taxes, and depreciation and amortization expense and “Adjusted EBITDA” reflects the adjustment to EBITDA to exclude stock-based compensation expense. A reconciliation of net loss to Adjusted EBITDA is provided in the table below.

  Three Months Ended
June 30,
  Six Months Ended
June 30,
 
  2023  2022  2023  2022 
Reconciliation of Adjusted EBITDA to net loss:                
Net loss $(104,156) $(228,034) $(264,286) $(537,429)
Income tax provision  58,137   26,916   59,667   28,813 
Interest income, net  (600,867)  (70,227)  (1,185,064)  (84,563)
Depreciation and amortization  958,001   713,180   1,803,017   1,392,351 
EBITDA  311,115   441,835   413,334   799,172 
Stock-based compensation  830,426   488,287   1,448,670   1,057,789 
Adjusted EBITDA $1,141,541  $930,122  $1,862,004  $1,856,961 

Liquidity and Sources of Capital Resources

 

The following table sets forth the major sources and uses of cash for the nine months ended September 30, 2017 and 2016:cash:

 

  Nine months ended September 30, 
  2017  2016 
Net cash provided by operating activities $4,133,672  $2,370,551 
Net cash (used) in investing activities  (1,250,795)  (603,559)
Net cash (used) in financing activities  (102,060)  (97,255)
Net increase in cash, restricted cash and cash equivalents $2,780,817  $1,669,737 
  

Six Months Ended June 30,

(Unaudited)

 
  2023  2022 
Net cash provided by operating activities $151,348  $16,399,465 
Net cash used in investing activities  (3,044,110)  (1,575,209)
Net cash used in financing activities  (968,067)   
Net increase in cash and restricted cash $(3,860,829) $14,824,256 

 1721 

Comparison of nineSix months ended SeptemberEnded June 30, 20172023 and 20162022

During the ninesix months ended SeptemberJune 30, 20172023 and 2016,2022, we financed our operations primarily through revenuesinternally generated from operations.funds.

 

OperatingCash provided by operating activities provided $4,133,672 of cash and restricted cash indecreased $16,248,117 for the ninesix months ended SeptemberJune 30, 2017,2023, as compared to $2,370,551 of cash and restricted cash in the same period in the prior year. RestrictedThe decrease is primarily due to changes in cash increased by $2,496,024 as a result of an increase in customer card funding. Major non-cash items that affected our cash flowflows from operations in the nine months ended September 30, 2017 were non-cash charges of $725,401 for depreciation and amortization and stock based compensation of $238,040. Our operating assets and liabilities, provided 1,957,469 of cash, most of which resulted from an increaseparticularly decreases in customer card funding of $2,496,024 a decrease$17,507,204 related to timing of customer deposits for plasma and pharma programs and an increase in prepaid expensesaccounts receivable of $(251,261) and a decrease in our legal settlement payable of $(254,900). Major non-cash items that affected our$2,973,641. These cash flow decreases were partially offset by cash flow increases of $621,264 primarily related to the collection of employee retention credits in the current year, increase in accounts payable and accrued liabilities of $2,621,446, an improvement in net loss from operations of $273,143, an increase in the nine months ended September 30, 2016 were non-cash chargesstock-based compensation of $406,328 for$390,881, and an increase in depreciation and amortization of $410,666. The changes in accounts receivable and stock based compensation of $40,091. Our operating assets and liabilities provided $1,125,181 of cash, most of which resulted from an increase in customer card funding of $1,726,127, offset by a decreaseaccounts payable are primarily related to the growth in our legal settlement payablepharma patient affordability business as we are invoiced by third party service providers at the end of $(746,954).the period and are due monies from our pharma patient affordability customers to cover these amounts due at the end of the period.

 

InvestingCash used in investing activities used $(1,250,795) of cash inincreased $1,468,901 for the ninesix months ended SeptemberJune 30, 2017,2023 as compared to $(603,559) of cash used in the same period in 2016,the prior year. The change between periods was primarily attributed to an increase in both periods, cash used in investing activities relatedthe capitalization of internally developed software as we continue to capital expenditures and the continuous enhancement of the processing platform usedinvest in our business.technology platform.

 

Financing activities used $(102,060) of cash in the nine months ended September 30, 2017 as compared to $(97,255) of cash used in the nine months ended September 30, 2016. In 2017, cashCash used in financing activities consistedincreased $968,067 for the six months ended June 30, 2023 as compared to the same period in the prior year. The change between periods was attributed to the repurchase of 319,558 shares of the company’s common stock at a weighted average price of $3.06 per share.

Our significant contractual cash requirements also include ongoing payments onfor lease liabilities. For additional information regarding our cash commitments and contractual obligations, see "Note 4 – LEASE” in the notes payables totaling $152,060 offset by $50,000 received fromto the exercise of a warrant. In 2016, cash used in financing activities consisted of payments on notes payables totaling $126,308 offset by $29,053 received from a note payable.accompanying consolidated financial statements.

  

Sources of FinancingLiquidity

We believe that our available unrestricted cash on hand, excluding restricted cash, at SeptemberJune 30, 20172023 of $1,916,736$7,670,677, along with our forecast for revenues and revenues anticipatedcash flows for the remainder of 2017and 20182023 and for 2024, will be sufficient to sustain our operations for the next twelveeighteen months.

Off-Balance Sheet Arrangements

We do In light of the recent bank failures, we continue to monitor the health and soundness of our bank relationships through publicly available information. Based on recent SEC filings, we have not havediscovered any off-balance sheet arrangementsissues that are reasonably likelywould cause us to have a current or future effect onalter our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.relationships.

 

Critical Accounting Policies and Estimates

Our significant accounting policies are described in Note 12 of the Notes to Consolidated Financial Statements. At this time, we are not requiredStatements of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make any material estimates and assumptions that affect the reported amounts and related disclosures of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses.  expenses during the reporting period. Actual results could differ from those estimates.

 

AnyOur estimates we make will beare based on our experience and our interpretation of economic, political, regulatory, and other factors that affect our business prospects. Actual results may differ significantly from our estimates.

22

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Because the Company iswe are a smaller reporting company, it iswe are not required to provide the information called for by this Item.

 

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and ProceduresProcedures.

Our chief executive officer and chief financial officer are responsible for establishing and maintaining our disclosure controls and procedures. Disclosure controls and procedures means controls and other procedures that are designed to ensure that the information we are required to disclose in the reports that we file or submit under the  Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and to ensure that information required to be disclosed by us in those reports is accumulated and communicated to the our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our chief executive officer and chief financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934)Act) as of SeptemberJune 30, 2017.2023. Based on that evaluation, our chief executive officer and chief financial officer have concluded that as of the evaluation date, suchour disclosure controls and procedures were effective.effective as of June 30, 2023, the end of the period covered by this Quarterly Report on Form 10-Q.

  

Changes in internal controlsInternal Control over Financial Reporting

There wereDuring the quarter ended June 30, 2023, there have been no changes in our internal controlscontrol over financial reporting that occurred during the quarter ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 1823 

 

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We

The Company has been named as a defendant in three complaints filed in the United States District Court for the District of Nevada: Yilan Shi v. Paysign, Inc. et. al., filed on March 19, 2020 (“Shi”), Lorna Chase v. Paysign, Inc. et. al., filed on March 25, 2020 (“Chase”), and Smith & Duvall v. Paysign, Inc. et. al., filed on April 2, 2020 (collectively, the “Complaints” or “Securities Class Action”). Smith & Duvall v. Paysign, Inc. et. al. was voluntarily dismissed on May 21, 2020. On May 18, 2020, the Shi plaintiffs and another entity called the Paysign Investor Group each filed a motion to consolidate the remaining Shi and Chase actions and to be appointed lead plaintiff. The Complaints are not presentlyputative class actions filed on behalf of a partyclass of persons who acquired the Company’s common stock from March 19, 2019 through March 31, 2020, inclusive. The Complaints generally allege that the Company, Mark R. Newcomer, and Mark Attinger violated Section 10(b) of the Exchange Act, and that Messrs. Newcomer and Attinger violated Section 20(a) of the Exchange Act, by making materially false or misleading statements, or failing to disclose material facts, regarding the Company’s internal control over financial reporting and its financial statements. The Complaints seek class action certification, compensatory damages, and attorney’s fees and costs. On December 2, 2020, the Court consolidated Shi and Chase as In re Paysign, Inc. Securities Litigation and appointed the Paysign Investor Group as lead plaintiff. On January 12, 2021, Plaintiffs filed an Amended Complaint in the consolidated action. Defendants filed a Motion to Dismiss the Amended Complaint on March 15, 2021, which Plaintiffs opposed via an opposition brief filed on April 29, 2021, to which Defendants replied on June 1, 2021. On February 9, 2023, the Court granted in part and denied in part Defendants’ Motion to Dismiss. As of the date of this filing, the Company cannot give any material litigation, normeaningful estimate of likely outcome or damages.

The Company has also been named as a nominal defendant in two stockholder derivative actions in the United States District Court for the District of Nevada. The first derivative action is entitled Andrzej Toczek, derivatively on behalf of Paysign, Inc. v. Mark R. Newcomer, et al. and was filed on September 17, 2020. This action alleges violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, and waste, largely in connection with the failure to correct information technology controls over financial reporting alleged in the knowledgeSecurities Class Action, thereby causing the Company to face exposure in the Securities Class Action. The complaint also alleges insider trading violations against certain individual defendants. On December 16, 2020, the Court approved a stipulation staying the action until the Court in the consolidated Securities Class Action issues a ruling on the Motion to Dismiss. The second derivative action is entitled John K. Gray, derivatively on behalf of management isPaysign, Inc. v. Mark Attinger, et al. and was filed on May 9, 2022. This action involves the same alleged conduct raised in the Toczek action and asserts claims for breach of fiduciary duty in connection with financial reporting, breach of fiduciary duty in connection with alleged insider trading against certain individual defendants, and unjust enrichment. On June 3, 2022, the Court approved a stipulation staying the action until the Court in the consolidated Securities Class Action issues a ruling on the Motion to Dismiss. On May 10, 2023, the Toczek and Gray actions were consolidated. The Company anticipates filing motions to dismiss given the ruling on the Motion to Dismiss in the consolidated cases. As of the date of this filing, the Company cannot give any litigation threatened against us, which may materially affect us.meaningful estimate of likely outcome or damages.

 

Item 1A. Risk Factors.

Not applicable.Because we are a smaller reporting company, we are not required to provide the information called for by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Issuer Purchases of Equity Securities

 

During the three monthsquarter ended SeptemberJune 30, 2017, the Company2023, we issued, 50,000 shares of common stock for current services rendered and 200,000 shares of restricted common stock to an employee. The shares were granted pursuant to an exemption from registration provided by Section 4(2)4(a)(2) of the Securities Act of 1933.1933, a total of 74,000 shares of common stock for restricted stock awards previously earned and vested to certain directors, consultants and employees and the exercise of stock options.

 

Item 3. Defaults upon Senior Securities.

 

None.

24

The following table sets forth certain information relating to the purchases of our common stock by us and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) under the Exchange Act during the three months ended June 30, 2023.

 

Period Total Number of Shares Purchased  Weighted Average Price Paid Per Share  Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)  Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs 
             
April 1, 2023 - April 30, 2023    $     $4,333,982 
May 1, 2023 - May 31, 2023  23,058   2.69   23,058   4,272,167 
June 1, 2023 - June 30, 2023  96,500   2.59   96,500   4,022,982 
Total  119,558  $2.61   119,558  $4,022,982 

Item 4. MINE SAFETY DISCLOSURES____________________

(1) On March 21, 2023, our board of directors authorized a stock repurchase program to repurchase up to $5 million of our common stock, subject to certain conditions, in the open market, in privately negotiated transactions, or by other means in compliance with Rule 10b-18 under the Exchange Act. The program is expected to be completed within 36 months from the commencement date.

None

 

Item 5. Other Information.Information

 

None.During the quarter ended June 30, 2023, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).

 

Item 6. Exhibits.

31.110.11Paysign, Inc. 2023 Equity Incentive Plan (1)
31.1*Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934Certifications
31.231.2*Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934Certifications
32.132.1*Certification Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Certifications
32.232.2*Certification Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Certifications
101.INSInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF104XBRL Definition Linkbase DocumentCover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101).

______________

* Filed herewith.

(1) Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 9, 2023 (File Number 001-38623).

 1925 

 

SIGNATURES

SIGNATURES

In accordance with

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 3PEA INTERNATIONAL,PAYSIGN, INC.
  
  
Date: November 13, 2017August 9, 2023/s/ Mark Newcomer
 

By: Mark Newcomer, Chief Executive Officer

(principal executive officer)

  
  
Date: November 13, 2017August 9, 2023/s/ Brian PolanJeff Baker
 

By: Brian Polan,Jeff Baker, Chief Financial Officer

(principal financial and accounting officer)

 

 

 

 

 

 

 

 

 

 

 

 

 2026